Deep Brain Stimulation for CBS/PSP

Deep Brain Stimulation for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Deep Brain Stimulation for CBS/PSP</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Subthalamic Nucleus (STN)</td>
</tr>
<tr>
<td class="label">Motor Improvement</td>
<td>Moderate (25-35%)</td>
</tr>
<tr>
<td class="label">Cognitive Risk</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Mood Effects</td>
<td>More common (depression, mania)</td>
</tr>
<tr>
<td class="label">Speech/Gait</td>
<td>May worsen</td>
</tr>
<tr>
<td class="label">Dyskinesia Control</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Medication Reduction</td>
<td>Significant (50-70%)</td>
</tr>
<tr>
<td class="label">Programming</td>
<td>More complex</td>
</tr>
<tr>
<td class="label">Battery Life</td>
<td>Shorter (3-5 years)</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Requirement</td>
</tr>
<tr>
<td class="label">Levodopa Response</td>
<td>≥30% improvement in "on" time</td>
</tr>
<tr>
<td class="label">Motor Complications</td>
<td>Fluctuations or dyskinesias not controlled with medications</td>
</tr>
<tr>
<td class="label">Age</td>
<td><75 years</td>
</tr>
<tr>
<td class="label">Cognitive Function</td>
<td>MMSE ≥24</td>
</tr>
<tr>
<td class="label">Psychiatric Status</td>
<td>No significant depression, psychosis</td>
</t

Deep Brain Stimulation for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Deep Brain Stimulation for CBS/PSP</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Subthalamic Nucleus (STN)</td>
</tr>
<tr>
<td class="label">Motor Improvement</td>
<td>Moderate (25-35%)</td>
</tr>
<tr>
<td class="label">Cognitive Risk</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Mood Effects</td>
<td>More common (depression, mania)</td>
</tr>
<tr>
<td class="label">Speech/Gait</td>
<td>May worsen</td>
</tr>
<tr>
<td class="label">Dyskinesia Control</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Medication Reduction</td>
<td>Significant (50-70%)</td>
</tr>
<tr>
<td class="label">Programming</td>
<td>More complex</td>
</tr>
<tr>
<td class="label">Battery Life</td>
<td>Shorter (3-5 years)</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Requirement</td>
</tr>
<tr>
<td class="label">Levodopa Response</td>
<td>≥30% improvement in "on" time</td>
</tr>
<tr>
<td class="label">Motor Complications</td>
<td>Fluctuations or dyskinesias not controlled with medications</td>
</tr>
<tr>
<td class="label">Age</td>
<td><75 years</td>
</tr>
<tr>
<td class="label">Cognitive Function</td>
<td>MMSE ≥24</td>
</tr>
<tr>
<td class="label">Psychiatric Status</td>
<td>No significant depression, psychosis</td>
</tr>
<tr>
<td class="label">Imaging</td>
<td>No significant cortical atrophy</td>
</tr>
<tr>
<td class="label">Disease Duration</td>
<td>Typically 5-15 years</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Moriarty et al. 2022</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Vallabhajosula et al. 2021</td>
<td>STN/GPi</td>
</tr>
<tr>
<td class="label">Pillon et al. 2019</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Odekerken et al. 2023</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Storch et al. 2021</td>
<td>STN</td>
</tr>
<tr>
<td class="label">Beaumont et al. 2020</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Range</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>130-185 Hz</td>
</tr>
<tr>
<td class="label">Pulse width</td>
<td>60-90 µs</td>
</tr>
<tr>
<td class="label">Voltage</td>
<td>1.5-4.0 V</td>
</tr>
<tr>
<td class="label">Contact configuration</td>
<td>Monopolar or bipolar</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Intracranial hemorrhage</td>
<td>1-2%</td>
</tr>
<tr>
<td class="label">Infection</td>
<td>1-3%</td>
</tr>
<tr>
<td class="label">CSF leak</td>
<td>1%</td>
</tr>
<tr>
<td class="label">Seizure</td>
<td><1%</td>
</tr>
<tr>
<td class="label">Complication</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Lead fracture</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">IPG malfunction</td>
<td>1-2%</td>
</tr>
<tr>
<td class="label">Skin erosion</td>
<td>1%</td>
</tr>
<tr>
<td class="label">Extension wire issues</td>
<td>1-2%</td>
</tr>
<tr>
<td class="label">Side Effect</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dysarthria</td>
<td>Both</td>
</tr>
<tr>
<td class="label">Cognitive decline</td>
<td>STN > GPi</td>
</tr>
<tr>
<td class="label">Mood changes</td>
<td>STN</td>
</tr>
<tr>
<td class="label">Gait worsening</td>
<td>Both</td>
</tr>
<tr>
<td class="label">Dyskinesias</td>
<td>Both</td>
</tr>
<tr>
<td class="label">Paresthesia</td>
<td>Both</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Cost (USD)</td>
</tr>
<tr>
<td class="label">Preoperative evaluation</td>
<td>$5,000-15,000</td>
</tr>
<tr>
<td class="label">Surgical procedure</td>
<td>$50,000-100,000</td>
</tr>
<tr>
<td class="label">Device (IPG + leads)</td>
<td>$30,000-50,000</td>
</tr>
<tr>
<td class="label">Programming visits</td>
<td>$2,000-5,000/year</td>
</tr>
<tr>
<td class="label">Battery replacement</td>
<td>$10,000-15,000</td>
</tr>
<tr>
<td class="label">Total first year</td>
<td>$90,000-150,000</td>
</tr>
<tr>
<td class="label">Annual maintenance</td>
<td>$5,000-15,000</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Target</td>
</tr>
<tr>
<td class="label">DBS for CBS: GPi vs Best Medical Care</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Adaptive DBS for CBS</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Long-term Outcomes CBS-DBS</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">DBS (GPi)</td>
<td>Moderate (CBS)</td>
</tr>
<tr>
<td class="label">Focused Ultrasound</td>
<td>Low (CBS)</td>
</tr>
<tr>
<td class="label">TMS</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>Moderate for CBS; Low for PSP</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Moderate (surgical risks + cognitive risk)</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Limited but promising for CBS; not recommended for PSP</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>Good at major centers</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Very high ($90-150K first year)</td>
</tr>
<tr>
<td class="label">Recommendation</td>
<td>Consider for carefully selected CBS patients with levodopa response; GPi target preferred</td>
</tr>
</table>

Deep Brain Stimulation (DBS) is an established neurosurgical treatment for movement disorders that involves implanting electrodes in specific brain regions to deliver electrical pulses. While DBS is FDA-approved and highly effective for [Parkinson's Disease](/diseases/parkinsons-disease), its role in [Corticobasal Syndrome (CBS)](/diseases/corticobasal-syndrome) and [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy) remains controversial due to limited evidence specific to these atypical parkinsonian syndromes[@deuschl2006].

This page provides a comprehensive analysis of DBS for CBS and PSP, including target selection (STN vs GPi), patient selection criteria, outcomes data, and surgical risks.

Mechanism of Action

DBS works by delivering high-frequency electrical stimulation (130-185 Hz) to target structures in the basal ganglia-thalamocortical circuits:

Unlike lesioning procedures, DBS is reversible and adjustable, allowing fine-tuning of stimulation parameters to optimize symptom control while minimizing side effects.

Target Selection: STN vs GPi

For CBS and PSP, target selection is critical and differs from Parkinson's Disease recommendations. The two primary targets have distinct efficacy and safety profiles:

Comparison Table

Recommendations for CBS/PSP

GPi is generally preferred over STN for CBS/PSP patients due to:

• Lower cognitive risk profile in tauopathies
• Better dyskinesia control
• More stable speech and gait outcomes
• Simpler programming requirements

• Significant medication reduction is desired
• Patient has robust cognitive reserve (MMSE ≥28)
• No psychiatric comorbidities

PSP-Specific Considerations

DBS for PSP is generally not recommended due to:

• Limited and inconsistent benefits
• High complication rates
• Axial symptoms (gait, balance, swallowing) typically unresponsive
• Cognitive decline often accelerates post-operatively

Patient Selection Criteria

Ideal Candidate for CBS DBS

Contraindications

• Significant cognitive impairment (MMSE <24)
• Active psychiatric disease (depression, psychosis)
• Major medical comorbidities (cardiac, pulmonary)
• Significant cortical atrophy on MRI
• Atypical parkinsonism without levodopa response
• Severe axial symptoms (freezing of gait, postural instability)
• Active dementia

Clinical Outcomes

CBS Outcomes

Evidence for DBS in CBS is limited to small case series and retrospective studies:

Key Findings:

• GPi-DBS may provide modest motor benefit (25-35% improvement)
• Asymmetric symptoms often improve more than symmetric
• Alien limb phenomenon generally unresponsive
• Cognitive decline is a significant risk

PSP Outcomes

DBS for PSP has shown limited to no benefit in most studies:

Bottom Line: DBS is not recommended for PSP due to:

• Lack of significant benefit
• High complication rates
• Potential for worsening axial symptoms

Surgical Procedure

Preoperative Evaluation

Surgical Steps

Programming Parameters

Surgical Risks and Complications

Surgical Risks (1-5%)

Hardware Complications

Stimulation-Related Side Effects

Long-Term Considerations

• Cognitive decline — May accelerate in some patients
• Speech/swallowing — Can worsen, especially with STN
• Battery replacement — Required every 3-7 years
• Stability — Benefits may diminish over time

Cost and Access

Financial Considerations

Insurance Coverage

• Medicare — Covers DBS for Parkinson's disease; CBS/PSP may require pre-authorization
• Private insurance — Most cover with prior authorization
• Coverage criteria — Typically require: confirmed diagnosis, levodopa response, motor complications

Access

• 250+ US centers perform DBS
• Academic medical centers — Mayo Clinic, UCSF, Columbia, Cleveland Clinic, Duke
• Wait times — 2-6 months for evaluation + surgery
• Second opinions — Strongly recommended

Decision Framework

When to Consider DBS for CBS

When to Avoid DBS for CBS/PSP

Current Research and Clinical Trials

Ongoing Studies

Emerging Technologies

• Directional leads — Current steering for fewer side effects
• Adaptive DBS — Closed-loop stimulation responsive to symptoms
• Chronic recording — Brain sensing for better programming

Comparative Analysis

DBS vs Other Device Therapies for CBS/PSP

Patient Action Items

NET Assessment

Bottom Line: DBS may provide modest benefit for carefully selected CBS patients with clear levodopa response and intact cognition. GPi targeting is recommended over STN. DBS is generally not recommended for PSP due to lack of benefit and high complication rates. Thorough pre-operative evaluation is essential, and patients must have realistic expectations.

See Also

• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Corticobasal Degeneration Treatment](/therapeutics/corticobasal-degeneration-treatment)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Parkinson's Disease DBS](/therapeutics/deep-brain-stimulation)
• [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
• [Focused Ultrasound](/therapeutics/focused-ultrasound-parkinson)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;